Production (Stage)
Ensysce Biosciences, Inc.
ENSC
$2.07
-$0.07-3.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.32M | 1.30M | 3.42M | 181.80K | 305.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.32M | 1.30M | 3.42M | 181.80K | 305.70K |
| Cost of Revenue | 1.89M | 3.80M | 1.69M | 947.20K | 778.90K |
| Gross Profit | -565.80K | -2.50M | 1.73M | -765.40K | -473.20K |
| SG&A Expenses | 1.40M | 1.08M | 1.08M | 1.19M | 1.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.29M | 4.88M | 2.77M | 2.14M | 2.15M |
| Operating Income | -1.97M | -3.58M | 644.70K | -1.96M | -1.84M |
| Income Before Tax | -1.95M | -3.56M | 661.80K | -1.97M | -3.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.95M | -3.56M | 661.80K | -1.97M | -3.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00 | -- | -- | 100.00 |
| Net Income | -1.95M | -3.56M | 661.80K | -1.97M | -3.12M |
| EBIT | -1.97M | -3.58M | 644.70K | -1.96M | -1.84M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.39 | -2.90 | 1.00 | -3.35 | -8.21 |
| Normalized Basic EPS | -0.87 | -1.81 | 0.63 | -2.09 | -5.13 |
| EPS Diluted | -1.39 | -2.90 | 1.00 | -3.35 | -8.21 |
| Normalized Diluted EPS | -0.87 | -1.81 | 0.63 | -2.09 | -5.13 |
| Average Basic Shares Outstanding | 1.40M | 1.23M | 659.40K | 587.80K | 379.60K |
| Average Diluted Shares Outstanding | 1.40M | 1.23M | 659.40K | 587.80K | 379.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |